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ABSTRACT
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According to the World Health Organization, Hepatitis C Virus (HCV) has infected 130150 million people worldwide. Approximately 700,000 of those die each year from chronic HCV
related causes such as cirrhosis or cancer. Currently, there are numerous HCV drugs on the
market; they target the protease, polymerase and NS5A proteins encoded by of HCV. These
drugs are expensive and HCV can become resistant, thus there is constant need for new DAAs.
The first part of this thesis examines the search for additional drugs that function by inhibiting
the NS3 helicase, which have been challenging to develop.
Part of the reason for a lack of helicase inhibitors can be due to the difficulty of
understanding its mechanism. The helicase is a motor protein that couples ATP hydrolysis to
DNA or RNA unwinding. The second part of this thesis examine the role of a cysteine residue in
the helicase ATP binding site. When the cysteine was replaced with other amino acids, the
protein possessed unusual features not seen in the wildtype helicase. Helicase proteins lacking
the cysteine, were able to hydrolyze ATP in the absence of nucleic acid 15times faster than
wildtype. This finding may provide future information into the coupling mechanism of chemical
energy to physical motions of the enzyme.
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Chapter 1: Literature Review
Section 1.1: Background
Hepatitis C Virus (HCV) [1] chronically infects an estimated 70 million people worldwide.
Of those, roughly four hundred thousand die each year from cirrhosis or liver cancer. According
to the CDC, one quarter of people with HIV also are co-infected with HCV. This complicates for
treatment of either disease and can increase risk for life-threatening complications. However,
with modern advances in disease research, numerous direct acting antivirals (DAAs) have been
created to effectively cure over 95% of all those living with HCV [2]. Current barriers to
treatment are cost and the lack of symptoms for many, while infected.
HCV is an enveloped virus which is transmitted via blood-to-blood contact. It primarily
infects the liver and can be asymptomatic for many years until it leads to liver disease. There is
no vaccine currently on the market, however, with extensive research of the viral proteins, in
2011, the first class of DAAs was released and offered a cure to many. Prior treatment, with
pegylated interferon and/or ribavirin, offered an increased chance for a person’s body to fight
off the infection, but had side effects and was an expensive treatment. The current treatments
have few side effects, and with insurance, can be an affordable cure. A culmination of research
in virology, biochemistry, and medicinal chemistry has provided relief for many.
HCV belongs to the Flaviviridae family of single-stranded, positive-sense RNA (+) ssRNA
viruses. Upon infection, the virus enters the cell and releases its genetic content. The (+) ssRNA
is like mRNA in eukaryotes; it does not need any modifications and is ready to be translated by
host ribosomes. The viral RNA is translated into a single polyprotein that is cleaved into mature
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proteins: structural (core, E1, and E2) and nonstructural (p7, NS2, NS3-4A, NS4B, NS5A, and
NS5B). The core, E1, and E2 are integral to the formation of core and envelope glycoproteins for
viral particle synthesis. NS2 and p7 support new viral particle formation, but are not
incorporated into the mature virus. NS3:NS4A, NS4B, NS5A and NS5B form the replicase
responsible for replicating the RNA viral genome. [3]
There are numerous HCV drugs on the market as well as many others in clinical trials.
The drugs can be administered as a single drug, or a combination of drugs targeting one, or
many HCV protein targets as well as genotypes. There are three main classes of HCV DAAs:
NS3/4A serine protease inhibitors, NS5A protein inhibitors, and NS5B RNA polymerase
inhibitors. I will discuss the current advances in each class.

Section 1.2: NS3 Protease Drugs -previr
NS3 is a multifunctional protein complexed with its cofactor, NS4A. NS3 is composed of
a serine protease in its N terminus, vital to polyprotein processing and viral replication, and a
NTPase/RNA helicase in its C-terminus. The NS4A cofactor is located at the C terminus of NS3.
[4].

NS4A is a short 54 a.a. peptide that is required for correct NS3 folding and NS3/4A

membrane tethering. Both the NS3 helicase and protease have been studied extensively, and
numerous crystal structures have been solved.
NS3 protease is a serine protease with a chymotrypsin-like fold, composed of 2 beta
barrels flanked by two alpha helices. The active site of the protease can accept between 6 and
10 amino acids; efficiency of the enzyme is best with ten. The NS4A cofactor helps position the
substrate into the active site and contributes to substrate specificity. General substrate
notation are the ten amino acid positions; P6 through P4’. The P1 – P1’ peptide bond is the one
2

cleaved; the scissile bond. The active site catalytic triad is composed of: His 57, Asp 81, and Ser
139. Lemke and associates demonstrate non-catalytic residues that are important to substrate
binding and in important for inhibitor design [5]. R155 and D168 form a salt bridge when
substrate is bound. The salt bridge induces the aliphatic chains of the residues to be exposed
forming a hydrophobic pocket in the active site. The general mechanism of the protease is well
known.
First, the substrate binds and is positioned correctly in the active site. The histidine
deprotonates the serine hydroxyl group thus activating to attack the carbonyl carbon of the
substrate. This create a tetrahedral intermediate. The amide bond is broken and electrons are
transferred to the histidine. This breaks the scissile bond and regenerates the histidine, while
the serine is still bound to the carbonyl carbon of the substrate. The N terminus of the
substrate exits, and a water enters that is activated by the histidine. The activated water attacks
the carbonyl carbon of the substrate forming another tetrahedral intermediate. A subsequent
electron transfer, kicks off the serine and regenerates both the His and Ser residues. The
carboxy-terminus of the substrate can now leave the active site. The aspartic acid residue acts
as a hydrogen bond acceptor from the delta amine of histidine. This subsequently pulls the
electrons from the epsilon nitrogen making it a better electrophile for attack on the serine
hydroxyl group. N-terminal peptides will serve as an important starting point for the
development of NS3 protease inhibitors [6].
Landro J. A. and associates showed that NS3 protease catalytic rate is substrate
sequence specific and amplified by about 5 times in the presence of cofactor NS4A [7]. NS3
protease is responsible for cleaving the translated initial polyprotein at: NS3/NS4A, NS4A/NS4B,
3

NS4B/NS5A, and NS5A/NS5B junctions for the activation of those proteins for viral replication
and particle formation. Research has cataloged the amino acid residue sequences as well as in
vitro catalytic rates; the cleavage of NS5A/NS5B is more efficient than other sites. The amino
acids essential for activity are an acidic residue in P6, a cysteine in P1, serine or alanine in P1’
and a hydrophobic residue in P4’. Steinkühler et al. showed that as substrate concentration
(DEMEEC-ASHLPYK-NH2 of the NS4A/NS4B site) was increased in steady state analysis, the
apparent Km increased as well, while no change observed for kcat [8]. Thus, the first example of
competitive product inhibition was discovered. The researchers aimed to confirm this was a
true observation and developed the N and C terminus polypeptides (DEMEEC-OH, ASHLPYIEQG)
and found that the N terminus substrate (DEMEEC-OH) competitively inhibited NS3 protease
with a Ki of 600 nM. They tested the substrates for the other junctions as well. Both the
NS4A/NS4B and NS5A/NS5B had Km values sub 10 µM and the N terminus peptides had Ki
values in the micromolar range. To note, there was no inhibition up to 500 µM substrate, with
the NS3/NS4A substrate. This show NS3 protease cleaves the NS3/NS4A junction and there is
no product inhibition. This evidence shows a possible target for drug development, as inhibition
at this junction could impede further polyprotein cleavage and thus halting viral proliferation.
The DEMEEC-OH peptide was further studied and optimized by Ingallinella et al. This
group optimized each possible position of P6-P1 to create the hexamer Ac-AspartateGlutamate-3,3-diphenylalanine-Glutamate-β-cyclohexaylalanine-Cysteine-OH (Ac-Asp-Glu-DifGlu-Cha-Cys-OH) [9]. This peptide substrate had a Ki of 50 nM and was a fundamental
contribution to the discovery of the first class of NS3 protease inhibitors; reversible covalent
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ketoamide binders boceprevir and telaprevir. Another class of inhibitors discovered were
reversible non-covalent ketoamide macrocycles.
The macrocycles are the current class of protease inhibitors on the market. The first
generation had three breakthrough drugs: Ciluprevir, BMS-605339, and MK-4519. Ciluprevir
was a P1-P3 macrocycle. It never reached the market due to safety issues in clinical trials. The in
vitro studies provided evidence of a potent inhibitor and important moieties that would lead to
improvements of further drugs. Llinas-Brunet and associates showed that a P1
vinylcyclopropylcaboxylic acid moiety that yields good solubility, good potency, and selectivity.
Ciluprevir also added to selectivity by making extra hydrogen bonds in the active site and
adding structural rigidity of the extended peptide [10].
Another key discovery was BMS605339 [11]. This was an acyclic molecule and instead of
a vinylcyclopropylcaboxylic acid at P1. Scola and team performed a structure activity
relationship, SAR, on a parent hexapeptide and determined a cycloproplacylsulfonamide in the
P1 position was best corresponding to a 50-fold decrease in IC50 (to 1 nM) than the carboxylic
acid. The sulfonamide moiety provides additional interactions with Gly137 and Ser139 in the
active site as well as maintains and ionic interaction with His57. While BMS605339 did not pass
clinical trials due to cytotoxicity, it provided the elucidation of the sulfonamide moiety.
Last, Liverton and associates showed that molecular docking of the inhibitors above,
revealed inhibitor P2 positions in an empty part of the protease crystal structure [12]. The
researchers determined that the empty electron density around the P2 position was missing
the NS3 helicase interaction. This is a valid consideration knowing that in vivo the NS3 is a
multifunctional protein. MK-4519 was determined through a structure activity relationship,
5

SAR, study by modeling and performing inhibitor studies in vitro with genotype 1b full length
NS3/4A. The vinylsulfonamide, from BMS-605339 was retained, the similar isoquinoline moiety
of ciluprevir and BMS-605339 in the P2’ position was simplified and MK-4519 was developed.
MK-4519 has a Ki sub nanomolar and an IC50 of about 5 nM. This compound is 50,000-fold more
selective to NS3 than tryspin or chymotrypsin; similar active site, proteases. While these three
compounds laid the ground work for future protease drugs, they had a few weaknesses: they
were susceptible to NS3 resistance mutations, they were expensive therapies, and they were
only effective on genotype 1b.
The current generation of macrocycles can cure HCV patients with most of the
genotypes without the need for interferon when combined, with a NS5A inhibitor, NS5B
inhibitor, or both. I will focus on two current protease inhibitors paritaprevir [13] and grazoprevir
[14].

Paritaprevir was developed by Abbott in 2010 and is a component of VIEKERA PAK. It is a

P1-P3 macrocycle with a acylsulfonamide, a P4 methyl pyrazine, and a phenanthridine moiety
at P2. The P4 and P2 moieties interact with D168 and R155 respectively. These are common
genotype 1 residues that can be mutated and confer resistance to inhibitors. Paritaprevir is
designed off the discoveries of previous protease inhibitors such as faldaprevir by Boeringer
Ingelheim [15]. D168 and R155 are common locations of mutations, and O’meara and team
discovered that reducing the interactions at those sites make the inhibitor less sensitive to
resistance. The P4 and P2 moieties are designed then to interact via hydrophobic interactions
rather than more specific interactions like hydrogen bonds or salt bridges. Paritaprevir has in
vitro IC50 in the low nanomolar range and is affective against genotypes 1a, 1b, 2a, 3a, 4a, and
6a, however, with reduced sensitivity to genotype 3a due to a D168Q mutation. Paritaprevir, as
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mentioned above, is a component of Viekera PAK. The other components are ombitasvir,
ritonavir and dasabuvir. The combined therapy is a new approach to target all stages of viral
replication; ombitasvir targets the NS5A multifunctional protein, dasabuvir targets the NS5B
RNA polymerase, and ritonavir (anti-HIV) targets cytochrome P450 to reduce the metabolism of
paritaprevir in the plasma. Viekera PAK can cure genotype 1a and 1b in 12 weeks and costs
between $80,000-$170,000, depending on duration of treatment required.
Grazoprevir was developed in 2012 by the Harper team at Merck [14]. It is a component
of Zepatier and while approved as a genotype 1 and genotype 4 cure, it is a potent inhibitor for
genotypes 1-6. Grazoprevir is a P2-P4 macrocycle containing an N terminal acylsulfonamide, a
P2 aromatic quinoxaline which decreases aqueous solubility causing the drug to have elevated
levels in the liver, and a P4 cyclopropyl group which allows space for A156 mutants. Grazoprevir
is an important drug molecule as it is a tight binder, low or sub-nanomolar concentrations, to
common genotype 1 mutants R155K, A156T, A156V, and D168V. Grazoprevir is combined with
elbasvir, a NS5A inhibitor. Zepatier can cure HCV genotype 1 and 4 in 12-16 weeks and is a
remarkably cheaper option starting at around $50,000 for 12 weeks.

Section 1.3: NS5B Polymerase Drugs -buvir
The NS3 protease inhibitors were the first HCV drugs on the market; NS5B polymerase
inhibitors followed shortly after. NS5B is a RNA polymerase necessary for viral RNA replication
but is error prone due to lacking proofreading mechanism. It is composed of 591 amino acid
and is homologous to other RNA dependent polymerases. It has 6 motifs, A-F, with the key
motif “GDD” located in the N-terminus and is membrane tethered by 21 amino acids in the Cterminus. The general shape of the polymerase is that of a right hand containing a finger, palm
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and thumb domain. NS5B has an encircled active site with numerous interactions between the
finger and thumb domains and uses two catalytic magnesium ions. The thumb domain contains
a β-hairpin loop, which influences the positioning of newly synthesized RNA, and can also
modulate the different modes of replication; either de novo without primer and create its own
dinucleotide to serve as a single stranded primer (closed polymerase) [16], or primer dependent,
transcribing from the 3’ end of a double stranded RNA molecule (open polymerase) [17]. The two
different modes of replication are remarkably different. The de novo process has two slow steps
followed by the rapid processivity of the polymerase. The two steps require the synthesis of
dinucleotide primer, followed by, the use of the newly synthesized primer. The next nucleotide
needs to be present in high concentration for elongation to occur. The presence of high
concentration of GTP stimulates the switch of synthesis to elongation [18].
There are two types of polymerase inhibitors available currently on the market on in
trials: nucleotide analogs, and non-nucleotide inhibitors. Nucleotide inhibitors are designed to
target the polymerase active site by being incorporated into the growing RNA strand but
hindering further elongation due to steric hindrance at the 2’ position on the ribose sugar. They
can be competitive inhibitors with regards to substrate nucleotides. Non-nucleotide inhibitors
are considered non-competitive as they do not compete with the substrate nucleotides, but
rather, they bind the polymerase and effectively block conformational changes required for
elongation steps [19]. The two drugs I will discuss are sofosbuvir, a nucleotide analog pro-drug,
and dasabuvir, a palm domain-specific inhibitor.
Sofosbuvir was developed by Pharmasset, acquired by Gilead, by the Sofia team [20].
Under the nucleoside class, there are three sub classes, β-D-2’-deoxy-2’-α-F-2’-β-C8

methylribose, β-D-2’-β-methylribose, and 4’-azidoribose classes. Sofosbuvir is a β-D-2’-deoxy2’-α-F-2’-β-C-methylribose prodrug that has a phosphoramidate moiety at the 5’ position on
the sugar. It was developed so that the phosphoramidate moiety would be cleaved and quickly
phosphorylated (30 minutes to 2 hours post-dose detection) to the active 2'-deoxy-2'-α-fluoroβ-C-methyluridine-5'-triphosphate in the liver. It is done so by hydrolyzing the carboxy ester by
human Cathepsin A. Next an elimination of the phenol forms an alaninyl phosphate metabolite
which is removed by histidine triad nucleotide-binding protein 1 to give the 2'-deoxy-2'-αfluoro-β-C-methyluridine-5'-monophosphate. Last, the monophosphate is phosphorylated
twice, first by UMP-CMP kinase, and then by nucleoside diphosphate kinase to give the active
triphosphate product [21]. The Sofia group showed that the more active diastereomer PSI-7977
could generate 29 µM triphosphate when incubated in hepatocytes with no cytotoxicity. Once
the active triphosphate is incorporated into the replicating RNA, the next nucleotide cannot be
added due to steric hindrance at the 2’ position. The active phosphate has sub to low
micromolar IC50 value in vitro inhibition for genotypes 1b, 2a, 3a, and 4a. The active
triphosphate is also not a substrate for other eukaryotic polymerases nor mitochondrial RNA
polymerase. In vivo studies by Lam and associates showed that the common mutation S282T
showed reduced susceptibility to the active triphosphate in genotypes 1b. 2a. 3a. and 4a [22],
however, still being able to cure HCV infection within 12 weeks. Sofosbuvir was approved by
the FDA in 2013 and is still currently on the market as part of a cross-genotypic cure, Epclusa.
Sovaldi, composed of only sofosbuvir, costs about $84,000 for a 12-week treatment and is
approved for genotypes 1-4. Epclusa is priced a little lower at about $75,000 for a 12-week
treatment.
9

The other type of polymerase inhibitor is a non-nucleotide inhibitor. Non-nucleotide
inhibitors can target the various structural domains of the polymerase: thumb, finger, or palm,
however, the lack of sequence conservation in these domains, the non-nucleotide inhibitors are
usually single genotype specific. Non-nucleotide inhibitors target allosteric sites on the thumb:
T1 and T2, the palm: P1 and P2, and the β-hairpin: P-β. Benzothiadiazine derivatives were
shown to be potent inhibitors of that targeted the P1 site, however were susceptible to
resistant variants. Dasabuvir was discovered by Liu and associates at Abbott [23]. It is an aryl
dihydrouracil derivative that acts by binding the polymerase palm domain with low nanomolar
IC50 for genotype 1a and 1b in vitro and also low nanomolar IC50 in vivo. Kati and team showed
dasabuvir’s specificity to HCV polymerase, not affecting various eukaryotic polymerases, as well
as catalogued resistant variants [24]. Dasabuvir is a component of Viekira PAK. It contains the
protease inhibitor paritaprevir, and the NS5A inhibitor ombitasvir. There is also ritonavir which
is necessary to suppress the activity of human cytochrome p450 isoform 3A4 (CYP3A4) which
will metabolize various inhibitors [25]. VIEKERA PAK can cure genotype 1a and 1b in 12 weeks
and costs about $80,000 for a 12-week treatment.

Section 1.4: NS5A Phosphoprotein Drugs -tasvir
The last type of HCV DAAs available is the class of NS5A inhibitors. NS5A is a
multifunctional, endoplasmic reticulum membrane associated, phosphoprotein. It is
responsible for viral replication and viral assembly as shown by Shirota [26]. Arima and
associates showed that NS5A can modulate hepatocyte growth by interacting with cyclindependent kinases; necessary for eukaryotic cell cycle proliferation and progression [27]. Ghosh
and associates showed that in mice, NS5A caused uncontrolled growth of fibroblasts and tumor
10

formation [28]. Last, Lan and associates showed the NS5A directly binds tumor suppressor p53.
By sequestering p53, apoptosis of HCV infected cells is decreased and therefore allows HCV
proliferation; contributing to liver cancer in chronic infections [29].
NS5A is composed of 447 amino acids with 4 distinct regions: The N-terminal
amphipathic helix, the serine rich phosphorylation cluster, the interferon sensing region
responsible for inactivating protein kinase R (host protein responsible for mounting a response
against viruses), and the proline rich cluster in the C-terminus [30]. The proline rich cluster is
conserved throughout all HCV genotypes and thus is a good drug target. The N-terminal helix is
required for functional NS5A and key mutations abolished HCV replication in vivo [31]. It is also
characterized as a zinc binding protein that can interact with viral RNA for replication. It is nonenzymatic and has a diverse but not well-defined role in the HCV lifecycle. I will focus on two
drugs, daclatasvir and velpatasvir, that have similar modes of inhibition and similar drug design.
Daclatasvir is a first generation NS5A inhibitor. It was developed by Bristol-Myers Squibb
in 2013. It was designed on SAR based off a symmetric NS5A inhibitor from Bristol-Myers
Squibb in 2009 [32]. This work provided the scaffold of a symmetric compound, that had
resistance to mutations in Domain I of NS5A; Y93H, L31V, and Q54L. The 2009 work also
showed that these NS5A compounds also inhibited hyperphosphorylation. Daclatasvir has IC50
values in the low picomolar range in vivo for genotypes 1a and 1b, sub-nanomolar IC50 for
genotypes 2-5, and is specific to HCV. Daclatasvir was also shown to interact only with domain 1
of NS5A and not with NS3 or NS5B. Ascher and associates show that daclatasvir competes with
RNA binding and by in silico docking showed the possible interactions at the dimer interface of
domain 1 [33]. Daclatasvir has a biphenyl core with symmetrical branched elements. Guedj and
11

team demonstrated daclatasvir is a potent inhibitor as it can block both RNA synthesis and virus
assembly [34]. Daclatasvir is marketed as Daklinza and was approved in 2015 to be used with
sofosbuvir to treat genotype 3 patients without interferon or ribavirin. The cost is about
$150,000 for a 12-week combined therapy.
Velpatasvir, a component of Epclusa, can treat HCV genotypes 1 through 6. It was
developed by Gilead in 2013 and was approved as a combination therapy with sofosbuvir in
2016. It has in vitro HCV inhibition at picomolar concentrations [35]. It binds in domain 1 and is a
defective substrate that competes with RNA. It is not symmetrical and thus the structure of it
makes it less sensitive to domain 1 common mutations than is daclatasvir. Both drugs contain
an imidazole proline component, however, velpatasvir also contains a benzopyrano imidazole
core which itself is not symmetric. Lawitz and associates showed that velpatasvir has better in
vitro activity against genotype 2 and 3 than daclatasvir [36]. Velpatasvir is also effective against
genotypes 1a, 1b, 2, 3, and 4 in patients mimicking the in vitro results of Cheng. Currently
Epclusa cost $75,000, and is a once a day pill for 12 weeks that cures HCV infection.

Section 1.5: Summary
The drugs covered above have shown the combined work of biochemistry, virology, and
medicinal chemistry. Combination therapies can target more genotypes and are also able to be
less sensitive to common resistant mutations. Here are a few current therapies that were
approved this year: Vosevi from Gilead (sofosbuvir/velpatasvir/voxilaprevir), MAVYRET from
Abbvie (glecaprevir/pibrentasvir). Both are pangenotypic and cheaper than EPCLUSA. HCV drug
development is continuing and new drugs are in clinical trials from Merck and Janssen [37]. HCV
therapies need to be developed as resistant mutations are discovered. The one protein not
12

mentioned in current therapies is the HCV NS3 helicase. NS3 helicase is a viable drug target as it
a necessary component to the HCV lifecycle and there are no current drugs that target NS3
helicase on the market.

Section 1.6: NS3 helicase Drugs
Various in silico studies have identified possible inhibitor scaffolds by utilizing molecular
docking programs like DOCK or ROCS. Once general properties of protein sites are identified,
drug molecules can be optimized. Another drug identification technique is to screen readily
available drug compound libraries in vitro or in vivo to identify a hit and further perform SAR to
optimize the inhibition of the compound. Chen et al. showed how the use of DOCK as a virtual
screening method of known compounds [40]. This study lead to the crystal structure of NS3h
with a blue HT dye bound in between domains 1 and 2. An earlier study by an Italian group,
identified a nucleotide mimicking inhibitor that was designed off a known HIV reverse
transcriptase selective molecule [41]. The two studies above helped guide further studies that
developed possible drug leads by using in silico screening of molecule design [42-45]. High
throughput screening of various compound libraries can also be used to identify possible drug
leads for SAR [46, 47]. Even with these recent discoveries, there are no helicase inhibitors on the
market yet. This is can be due to low potency, drug resistance, and cell cytotoxicity. Finding
helicase inhibitors is critical due to variability of the virus genome, cost of current treatments,
and limited access to impoverished areas where blood borne diseases are more prevalent.
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Chapter 2: Methods
Section 2.1: Site Directed Mutagenesis and Protein Expression
pET24a-Hel-2a(JFH) plasmid DNA was extracted and purified using ThermoFisher
GeneJet plasmid prep kit from previous work [49]. Plasmid DNA was confirmed on a 1% agarose
DNA gel. To create the C292G mutation, mutagenic primers were designed (IDT, Coralville, IA)
harboring the desired nucleotide mutation, thymine to guanine as highlighted below.
C292G (+) 5’-CATCATCATATGCGATGAAGGCCACG-3’
C292G (-) 5’-GTAGCATCCACAGCGTGGCCTTCATC-3’
Plasmid DNA was amplified with primers as described by site directed mutagenesis kit
QuikChange II XL from Agilent Technologies. After the PCR, products were used to transform
into E. coli XL10 cells. Transformed E. coli were plated on LB Kanamycin and selected after
incubation. Successfully transformed colonies’ plasmid DNA were extracted and purified using
GeneJet kit (ThermoFisher) following the manufacturer’s instructions. Selected plasmids were
sequenced (Genewiz, South Plainfield, NJ) before expression and protein purification. Plasmids
harboring the desired point mutation were used to transform BL21(DE3) cells as described by
Hanson et al. [50]. The new plasmid was named pET24a-Hel-2a(JFH)C292G for storage.
Expression and purification yielded about 5 mg of helicase from 2 liters of culture. This is lower
than described by Lam et al., [49] possibly due to transformation inefficiency with the cells used
at the time and shortened time of culture incubation. Wildtype genotype 2a (JFH1 stain) NS3
helicase was expressed and purified as described above and yielded about 10 mg of helicase
from 2 liters of culture, in line with what was reported before.
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Section 2.2: Colorimetric ATP Hydrolysis Assays
Initial characterization of the two enzymes was done using a colorimetric ATPase assay,
with rates determined from measurements are taken at defined time points. The endpoint
assay utilized malachite green, which is sensitive up to 300 µM inorganic phosphate. 30 µL
reactions were set up in 96 well clear UV plates as reported by Ndjomou et al. [51]: 25 mM
MOPS, pH 6.5, 1.25 mM MgCl2, 5 µg/ml BSA, 0.01% (v/v) Tween20, 150 µM Poly-U RNA, 0–100
nM NS3h, and 1 mM ATP. All components except ATP were mixed. Reactions were initiated
with ATP and terminated upon addition of the malachite green solution after 15 minutes at
25oC. ATPase assays were also performed in the absence of RNA following the conditions
above, initiated with 100 µM ATP, and utilized the coloring agent BioMol Green (Enzo Life
Sciences).

Section 2.3: Continuous coupled ATP Hydrolysis Assay
To confirm the activity seen in the endpoint ATPase assay above, a continuous ATP
hydrolysis assay was used in which phosphate production was coupled the action of purine
nucleoside phosphorylase [52]. Conditions were: 20 mM pH 7.6 Tris, 1mM MgCl2, 150 µM Poly-U
RNA, 200 µM ATP, 100µM 2-amino-6-mercapto-7-methylpurine (Invitrogen), 2.5U/mL Purine
nucleoside phosphorylase (Sigma Aldrich), and varying concentrations of NS3h to initiate the
assay. Absorbance change was converted to nM phosphate released/second following the
protocol described by Webb [52].

Section 2.4: DNA Binding Assay
The DNA binding assay is a fluorescence experiment designed to monitor the anisotropic
effect of NS3h binding to Cyanine 5 tagged oligonucleotide as described [53]. Conditions were:
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25mM Mops pH 6.5, 1.25mM MgCl2, 5nM Cy5’-dT15, and varying concentrations of NS3h.
Fluorescence anisotropy measurements were obtained on a TECAN M1000 PRO at 25 oC.

Section 2.5: Helicase Unwinding Assay
A Molecular Beacon-based Helicase Assay (MBHA) was used to monitor the ability of
HCV helicase to unwind a DNA substrate. The method was followed as described previously [54].
Assays were performed in a cuvette or a microplate utilizing a Varian Cary Eclipse, or Varioskan
Plate reader to collect data. Assay final conditions after addition of 10 mM ATP were as follows:
25 mM MOPS, pH 6.5, 1.25 mM MgCl2, 0.01% Tween20, 5 µg/mL BSA, 10 nM MBHA substrate,
1 mM ATP, and varying concentrations of NS3h. ATP was used to initiate the assay.

Section 2.6: Intrinsic Protein Fluorescence
Intrinsic protein fluorescence can be monitored by observing fluorescence emission at
340 nanometers, while exciting a protein solution at 280 nanometers. First, enzyme
concentration was confirmed by absorbance. 100 nM enzyme was used for the assay. Next, the
extinction coefficient was calculated for the compound by taking absorbance reading at A 280
and A340. This was done to further correct for inner filter effects Fcorr=Fobs*10^((Aex+Aem)/2).
Next, the drug compound was titrated into a reaction mixture (25 mM MOPS, pH 6.5, 1.25 mM
MgCl2, 0.01% Tween20) that does not contain enzyme. This was done to account for either a
fluorescent compound or an absorbent compound at the respective wavelengths. This
generates a baseline fluorescence/absorbance profile for the compound. Last, the drug
compound was titrated into the same reaction mixture, containing 100 nM helicase and
fluorescence is observed over a range of inhibitor concentration. Data was corrected for
volume dilution effect, inner filter effect, and compound fluorescence. Resulting data was then
16

corrected data which is plotted against total inhibitor concentration. Data was fit to a one-site
binding equation Y = Bmax*X/(Kd + X) or the quadratic equation (see Fig. 2, legend) to calculate
the dissociation constant, Kd.
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Chapter 3: Screening for DAAs targeting HCV helicase
Five distinct classes of newly synthesized drug compounds were screened using methods
from sections 2.2, 2.4, and 2.5. The following chapter contains data excerpts from the following
works:
•

•

•

•

•

Marcella Bassetto, Pieter Leyssen, Johan Neyts, Mark M. Yerukhimovich, David N. Frick,
and Andrea Brancale. "Shape-based Virtual Screening, Synthesis and Evaluation of Novel
Pyrrolone Derivatives as Antiviral Agents against HCV." Bioorganic & Medicinal
Chemistry Letters 27.4 (2017): 936-40.
Marcella Bassetto, Pieter Leyssen, Johan Neyts, Mark M. Yerukhimovich, David N. Frick,
Matthew Courtney-Smith, and Andrea Brancale. "In Silico Identification, Design and
Synthesis of Novel Piperazine-based Antiviral Agents Targeting the Hepatitis C Virus
Helicase." European Journal of Medicinal Chemistry 125 (2017): 1115-131.
Marcella Bassetto, Salvatore Ferla, Pieter Leyssen, Johan Neyts, Mark M Yerukhimovich,
David N Frick, Rachel O'Donnell, and Andrea Brancale. "Novel Symmetrical
Phenylenediamines as Potential Anti-Hepatitis C Virus Agents." Antiviral Chemistry &
Chemotherapy (2016): Antiviral Chemistry & Chemotherapy, 04 November 2016.
Marcella Bassetto, Pieter Leyssen, Johan Neyts, Mark M. Yerukhimovich, David N. Frick,
and Andrea Brancale. "Computer-aided Identification, Synthesis and Evaluation of
Substituted Thienopyrimidines as Novel Inhibitors of HCV Replication." European Journal
of Medicinal Chemistry 123 (2016): 31-47.
Neerja Kaushik-Basu, Nina K. Ratmanova, Dinesh Manvar, Dmitry S. Belov, Ozge Cevik,
Amartya Basu, Mark M. Yerukhimovich, Evgeny R. Lukyanenko, Ivan A. Andreev, Grigory
M. Belov, Giuseppe Manfroni, Violetta Cecchetti, David N. Frick, Alexander V. Kurkin,
Andrea, Altieri, and Maria Letizia Barreca. "Bicyclic Octahydrocyclohepta[b]pyrrol-4(1H)
one Derivatives as Novel Selective Anti-Hepatitis C Virus Agents." European Journal of
Medicinal Chemistry 122 (2016): 319-25.

Section 3.1: Novel Pyrrolone Inhibitors
A ligand-based approach was applied to screen in silico a library of commercially
available compounds, with the aim to find novel inhibitors of the HCV replication starting from
the study of the viral NS3 helicase. Six structures were selected for evaluation in the HCV sub
genomic replicon assay and one hit was found to inhibit the HCV replicon replication in the low
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micromolar range. A small series of new pyrrolone compounds was designed and synthesized,
and novel structures were identified with improved antiviral activity (Fig. 1, Table I).

Section 3.2: Novel Piperazine Inhibitors
A structure-based virtual screening of commercial compounds was carried out on the
HCV NS3 helicase structure, with the aim to identify novel inhibitors of HCV replication. Among
a selection of 13 commercial structures, one compound was found to inhibit the sub genomic
HCV replicon in the low micromolar range. Different series of new piperazine-based analogues
were designed and synthesized, and among them, several novel structures exhibited antiviral
activity in the HCV replicon assay. Some of the new compounds were also found to inhibit HCV
NS3 helicase function in vitro, and one directly bound NS3 with a dissociation constant of 570 ±
270 nM (Figure 2, Table II).

Section 3.3: Novel Thieno-pyrimidine Inhibitors
A structure-based virtual screening technique was applied to the study of the HCV NS3
helicase, with the aim to find novel inhibitors of the HCV replication. A library of ~450,000
commercially available compounds was analyzed in silico and 21 structures were selected for
biological evaluation in the HCV replicon assay. One hit characterized by a substituted thienopyrimidine scaffold was found to inhibit the viral replication with an EC50 value in the submicromolar range and a good selectivity index. Different series of novel thieno-pyrimidine
derivatives were designed and synthesized; several new structures showed antiviral activity in
the low or sub-micromolar range (Fig. 3, Table III and IV).
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Section 3.4: Novel symmetrical phenylenediamine Inhibitors
Despite the great progress made in the last 10 years, alternative strategies might help
improving definitive treatment options against hepatitis C virus infection. With the aim of
identifying novel inhibitors of the hepatitis C virus-1b replication targeting the viral NS3
helicase, the structures of previously reported symmetrical inhibitors of this enzyme were
rationally modified, and according to docking-based studies, four novel scaffolds were selected
for synthesis and evaluation in the hepatitis C virus-1b sub genomic replicon assay. Among the
newly designed compounds, one new structural family was found to inhibit the hepatitis C
virus-1b replication in the micromolar range. This scaffold was chosen for further exploration
and different novel analogues were synthesized and evaluated. Different new inhibitors of the
hepatitis C virus genotype 1b replication were identified. Some of the new compounds show
mild inhibition of the NS3 helicase enzyme (Table V).

Section 3.5: Novel Bicyclic octahydrocyclohepta[b]pyrrol-4(1H) one Inhibitors
We report the discovery of the bicyclic octahydrocyclohepta[b]pyrrol-4(1H)-one scaffold
as a new chemotype with anti-HCV activity on genotype 1b and 2a sub genomic replicons. The
most potent compound 34 displayed EC50 values of 1.8 µM and 4.5 µM in genotype 1b and 2a,
respectively. Compound 34 moderately inhibits helicase unwinding with an IC50 of 300 µM and
binds helicase with a Kd of 1.1 µM (Fig. 4, Table VI).
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Chapter 4: Role of Cys292 in Coupling RNA binding to Helicase-catalyzed
ATP Hydrolysis
Section 4.1: Background
HCV NS3h is a super family 2 helicase composed of 3 domains, Rec A-like domains 1 and
2, and domain 3. The helicase has two important catalytic functions that are linked together:
ATP hydrolysis and DNA binding/unwinding. The space between domains 1 and 2 forms the ATP
binding site (Fig. 5). The groove between domain 3 and the Rec A like domains, forms the
DNA/RNA binding site. NS3h belongs to superfamily 2 helicases and encodes conserved regions.
One of those regions is the ATPase site which contains Walker Type A and B motifs [38]. NS3h
has a conserved 4 residue active site for ATP hydrolysis; DECH box protein. D, E and H, in the
Walker B motif (Fig. 5A), function as a metal binding motif that coordinates with the divalent
metal cofactor required to activate a water for nucleophilic attack of the γ-phosphate of ATP.
Lysine 210, from the Walker type A motif, additionally coordinates the magnesium ion in the
active site. Substitutions of other amino acids in the ATPase site in place of the D290, E291, or
H293 in Walker B motif, or K210 in Walker A motif, render a defective helicase. Here,
substitutions for the C292 in this motif are examined, and they are compared with similar
substitutions made elsewhere in the proteins outside the ATP binding site (Fig. 5B). The DNA
binding/unwinding site includes by conserved residues T269, T411, R467, W501, and V432 that
are all critical to helicase function [39]. The cleft between domains 1 and 2 opens and closes
upon ATP binding and hydrolysis causing the protein to move on DNA like an inchworm (Fig. 6).
ATP and RNA (or DNA) can bind independently to HCV helicase, but only when both are
bound together will the helicase rapidly hydrolyzed ATP to fuel its motions on RNA (kfast, Fig. 7).
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The experiments in this chapter were designed to test how Cys292 coordinate helicase action
by measure Kd, Km, Km*, KRNA, kfast and kslow for HCV helicase isolated from two different
genotypes (1b and 2a) and compare the values with those obtained using helicases in which
Cys292 is replaced with a Gly (C292G).

Section 4.2: Results
Site directed mutagenesis was used to generate a plasmid encoding genotype 2a HCV
helicase harboring a C292G substitution, and its sequence confirmed by DNA sequencing (Fig,
8).
Unwinding assays reveal very different activity for the two enzymes (Fig. 9). At low
concentrations of enzyme, C292G has a significantly lower unwinding rate than wild type. This
difference in unwinding rates might be due to the mutant enzyme unwinding fewer base pairs
per binding event. The C292G unwinding velocity reaches steady state at high (>500nM)
helicase concentration supporting the idea the mutant is less processive than wild type; wild
type reaches Vmax at about 100 nM. It can be seen from Fig. 9 that above 100 nM, wild type
helicase, the velocity begins to decline, whereas with the C292G protein rates continues to
increase in velocity. This may be due to aggregation of wildtype and steric hindrance as more
helicase molecules crowd on the MBHA substrate. The short lag phase for the mutant, seen in
Fig. 9, below 100 nM may suggest a few mechanisms. It is possible that the mutant is constantly
in the open conformation and thus it takes longer to go through energetic motions to
effectively hydrolyze ATP and unwind the substrate. This may not hold true, if the DNA binding
isotherms are similar and thermodynamically the same between wild type and mutant. Another
possibility is that the mutant binds the MBHA substrate and the open ATPase site is too mobile
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and therefore cannot achieve optimal active site configuration. At low enzyme concentration,
this might explain the slower rates. At higher concentrations, the fluorescence is a collective
measurement of all the substrate being unwound thus no lag is observed.
To probe why the C292G protein might be different from wildtype, we designed
experiments to compare Kd, Km, Km*, KRNA, kfast and kslow (Fig. 7) for C292G and the wildtype
protein.
In the first set of assays, the dissociation constant describing DNA binding (Kd,) was
found to be similar for both enzymes (Fig. 10). Others have shown that HCV helicase binds DNA
tightly with a ΔG of about -50 kJ/mol [48]. We calculated ΔG of about -51 kJ/mol which concurs
with the value previously reported. Both the wild type and C292G mutant bind DNA with similar
affinity (Fig. 10). The dissociation constant describing the interaction of RNA in the presence of
ATP was probed by determining the amount of RNA needed to stimulated helicase catalyzed
ATP hydrolysis by 50% KRNA. The KRNA was about 50% lower for the C292G protein than the
wildtype, suggesting a slightly tighter interaction in the presence of ATP (Fig 11).
Both C292G and wildtype have the same ATP hydrolysis rate in the presence of Poly U
RNA (Figs. 12, 13). When bound to RNA, the two enzymes have similar turnover rates (Fig. 11),
and the observed Km for ATP is similar for both proteins (Fig. 12).
In contrast, the wildtype and C292G enzymes behave dramatically different in the
absence of RNA (Figs. 14, 15). When the enzyme is not bound to RNA, the C292G substitution
yields a helicase that can hydrolyze ATP 15 times faster than wildtype in the absence of Poly U
RNA (Fig. 14), and the Km for ATP is almost 10 times higher in reactions catalyzed by C292G
(Fig. 15), suggesting that ATP binds C292G weaker than wildtype.
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Combined, these data also show that the wildtype is stimulated over 20-fold in the
presence of nucleic acid, but the C292G protein is only stimulated 1.5-fold. The hypothesis of a
mobile ATPase site is supported by the higher Km value for the C292G, where enzyme
concentration is 10 nM and the Km for ATP is about 10 times higher than the wildtype. Figure 12
confirms that ATP hydrolysis affinity for ATP is similar in the presence of RNA for both enzymes.

Section 4.3: Conclusions
The data presented within gives insight as to the importance of the Cys292 residue. The
absence of the cysteine residue may confer an open conformation of the ATPase site that
allows for hydrolysis to occur in the absence of nucleic acid. With the more open ATPase site, it
may take longer for proper contact to be made for rapid unwinding. ATP binding weakens the
helicase-DNA affinity and thus results in a weakly bound state. In this weakly bound state, the
helicase can translocate along nucleic acid. Rapid ATP hydrolysis and release of phosphate
returns the helicase to a tightly bound conformation with respect to the DNA [55]. The repetition
of this cycle causes helicase translocation from 3’ to 5’. The similar affinity for DNA shows that
the C292G helicase is functional. The activity is further supported by the stimulated ATPase
results, showing specific activities are similar for both enzymes. The unstimulated ATPase data
show that the mutant can hydrolyze ATP without RNA substrate. That may mean there are
more enzymatic motions throughout that break the link of ATP hydrolysis to helicase
translocation. That result, coupled with the very different behaviors seen in the unwinding
data, may show that the cysteine is necessary to link ATP hydrolysis and helicase unwinding.
In unwinding assay (Fig. 9), at above 100 nM wild type helicase the velocity begins to
decline whereas unwinding catalyzed by C292G continues to increase in velocity. This may be
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due to aggregation of wildtype and steric hindrance as more helicase molecules crowd on the
MBHA substrate. The sigmoidal shape of the curve with the C292G protein (Fig. 9), below 100
nM, may suggest a few mechanisms. It is possible that the mutant is constantly in the open
conformation and thus it takes longer to go through energetic motions to effectively hydrolyze
ATP and unwind the substrate. This may not hold true, as the DNA binding curves are very
similar and thermodynamically the same between wild type and mutant. Another possibility is
that the mutant binds the MBHA substrate, and the open ATPase site is too mobile and
therefore cannot achieve optimal active site configuration. At low enzyme concentration, this is
seen as the lag phase. At higher concentrations, the fluorescence is a collective measurement
of all the substrate being unwound.
Since the C292G protein displays the peculiar DNA unwinding characteristic (Fig. 9), it
would be interesting to crystalize and using nucleoside analogs, as demonstrated by Gu and
Rice [56], to visualize the conformations of apoenzyme, DNA bound, DNA and ATP bound, and
DNA and ADP and Pi bound, to understand what step of the enzymatic pathway causes the
visible result. The substitution to a glycine would occupy less space in the active site, as well as
reduce any electrostatic or steric interaction. From the data presented within, cysteine 292
plays a critical role in linking ATP hydrolysis to DNA unwinding.
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TABLES

Table I: Pyrrolone compound screening results. 9 synthesized compounds were screened using
an in vitro Helicase Unwinding assay, shown in the last column. Compound 7c had moderate
inhibition of 438 µM however was cytotoxic above 97 µM.
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Table II: Piperazine compound screening results. 58 synthesized compounds were screened
using an in vitro Helicase Unwinding assay, shown in the last column. Compound 31 had the
best inhibition of the compounds and was selected for further in vitro analysis.
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Table III: Selected Thieno-pyrimidines for helicase inhibition analysis. 8 compounds were
selected for further in vitro testing utilizing ATP hydrolysis assay in the presence and absence of
Poly U RNA, and DNA binding inhibition.
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Table IV: Thieno-pyrimidine Helicase unwinding assay results. 41 thieno-pyrimidine
derivatives were screened for inhibition of helicase unwinding. Only four compounds yielded
measurable inhibition.
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Table V: Phenylenediamine derivatives and HCV genotype 1b inhibition. A series of 14
compounds were screened for helicase unwinding inhibition. 4 compounds had moderate
unwinding inhibition, as seen in the last column.
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Table VI: Octahydrocyclohepta[b]pyrrol-4(1H) one derivatives and cell based inhibition. Table
shows the cell based inhibition screening in HCV genotypes 1b and 2a. Helicase unwinding data
not shown. Compound 34 has the most potent in vivo inhibition of HCV replicon.
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FIGURES

Figure 1: Structure of synthesized novel pyrrolone HCV NS3h inhibitor 7c. HCV unwinding
assay was performed to characterize the inhibition of 7c on HCV helicase. Compound had
moderate IC50 of 438 µM.
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Figure 2: Piperazine compounds and relevant in vitro screening results. (a) Structures of novel
synthesized symmetrical and non-symmetrical piperazine inhibitors. (b) DNA binding assay
monitoring percent of displaced ssDNA as a function of inhibitor concentration. Data fit to IC 50
inhibition equation and numbers list represent 95% confidence intervals of the nonlinear
regression. (c) Ability of each compound to inhibit NS3 helicase-catalysed ATP hydrolysis.
Numbers in parenthesis are as in (b). (d) Rates of ATP hydrolysis (nM ATP cleaved/s/nM NS3h)
observed in the presence of various concentrations of poly(U) RNA and 31. Data are globally fit
to V=(Vmax*R/KRNA + R) + Vb assuming 31 does not affect Vmax. (e) Amount of RNA needed to
stimulate ATP hydrolysis to 50% maximum (KRNA) observed at various concentrations of 31. (f)
Intrinsic Protein Fluorescence observed with various concentrations of 31 in the absence of
NS3h (circles) or in the presence of 100 nM NS3h (squares). Data are globally fit to F=Fe*(E – EL)
+ Fs*(L – EL) + Fc*(EL) where EL= ((Kd + L + E) - sqrt((Kd + L + E)2 - 4*(L*E))))/2 with the noted
dissociation constant and an Fe of 308, Fs of 4.5. and Fc of 641. L is the total concentration of
compound 31, E is the concentration of NS3h, Kd is the dissociation constant describing complex
formation, Fe is coefficient describing free protein fluorescence, Fs is a coefficient describing
free compound 31 fluorescence, and Fc is a coefficient describing the fluorescence of the
protein-ligand complex.
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Figure 3: Structure of Thieno-pyrimidine compound 1a. Compound did not inhibit the helicase
unwinding assay.

34

Figure 4: Intrinsic Protein Fluorescence for Determination of Kd. Intrinsic Protein Fluorescence
observed with various concentrations of 34 in the presence of 100 nM NS3h genotype 1b. Data
are fit to the one-site specific binding equation Y = Bmax*X/(Kd + X) to calculate the Kd for
specific binding for compound 34. Compound 34 had similar in vivo IC50 inhibition concentration
in genotypes 1b and 2a.
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Figure 5: Positions of Cysteines in of HCV helicase. Structures were modeled from PDB ID 3KQL
showing ATPase site with ADP*AlF4 and the helicase bound with substrates. (a) Structure of
ATPase active site and conserved residues of Walker Type A Motif K210, and Walker type B
motif D290, E291, C292, and H293, shown bound with ADP AlF4 and a magnesium ion. (b)
Structure of NS3h bound to ssDNA and ADP*AlF4 nucleotide analogue. Highlighted Cysteine
residues in this study that were mutated are shown in spheres.
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a.

b.

Figure 6: Structures of open and closed HCV helicase conformations. (a.) 3KQH (open ATPase
site, green) superimposed on 3KQN (closed ATPase site, red) showing the motions of the overall
enzyme and (b.) the motions within the ATPase site. Mainly Domain 2 rotates around 1 and 3
upon binding of DNA and ATP. The cysteine is noted by a yellow star in (b) and does not move
much relative to the other residues suggesting it may have a key role in an electrostatic
interaction.
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Figure 7: Random Sequential Mechanism of ATP and RNA binding to HCV helicase.
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Figure 8: DNA Sequencing results showing the desired mutation encoding C292G. After PCR,
plasmids were transformed into E. coli. Colonies that grew were selected and the plasmid DNA
was extracted and sent for sequencing. Sequencing results were aligned to produce the figure
above. The 03192014 plasmid was used to make the recombinant helicase.
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Figure 9: Helicase unwinding assay with the wildtype and C292G helicases Molecular beacon
helicase assay was used to characterize the unwinding of the mutant C292G versus the
wildtype. Various concentrations of both enzymes were used. The raw data (right) was fit to a
user defined equation [54]. The fit exported a DNA unwinding rate, a.u./sec, which is the initial
velocity time the amplitude. The rates were then fit to Michaelis Menten equation to estimate
Vmax. Two remarkably different enzymes can be seen. It takes about 5 times more of mutant
helicase to reach a similar unwinding rate as 50nM wildtype. It is also visible that the mutant
may undergo a slower mechanism at lower concentrations as there is a small lag phase up to
100 nM enzyme concentration.
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Figure 10: DNA binding assays to characterize dissociation constant for ssDNA. Enzyme is
titrated into a premix containing 10 nM ssDNA Cy5’-dT15. Fluorescence anisotropy is measured
and data is fitted to a one site substrate binding equation Y = Bmax*X/(Kd + X). Genotype 2a
wild type and C292G mutant have similar affinity for single stranded DNA confirming the
mutation in the ATPase did not affect the nucleic acid binding site.
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Figure 11: ATPase assay to approximate enzyme affinity for Poly-U RNA (KRNA). A stimulated
ATPase assay was used to characterize the affinity for RNA. A reaction mixture containing 10nM
helicase was pipetted into a 96 well plate. A 16-point dilution of Poly U RNA was added to the
wells and the assay was initiated with 10mM ATP. Reaction was run for 900 seconds at which
point it was quenched by the coloring reagent. Data was converted to velocity (s-1) and plotted
against RNA concentration. Then data was fit with the Michaelis Menten equation, where Km
was used as an approximation for affinity for RNA. The C292G mutant is faster at hydrolyzing
ATP and binds RNA slightly tighter than wildtype.
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Figure 12: Stimulated ATPase to characterize specific activity in the presence of RNA. Enzyme
was premixed with Poly-U RNA and the assay was initiated with 10 mM ATP. An endpoint
malachite green assay was used quench the reaction after 900 seconds. Absorbance data were
converted to nM/sec rates using a known phosphate standard. Rates were plotted and fit with
a linear regression to generate the figure above. The single Cys292 mutant behaved similar to
the wildtype showing the C292G enzyme is still active.
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Figure 13: Stimulated ATPase assay to estimate affinity for Mg*ATP. Enzyme was premixed
with Poly-U RNA and the assay was initiated with 10mM Mg*ATP. An endpoint malachite green
assay was used to detect the hydrolysis of ATP over 900 seconds. Results were plotted and fit
with a Michaelis Menten equation to estimate the affinity of NS3h to Mg*ATP. Data varied
between the genotype 1b enzymes, however, the 2a wildtype and the 2a C292G mutant
behaved similarly. This shows both enzymes hydrolyze ATP similarly in the presence of nucleic
acid. High concentrations of magnesium are known to inhibit helicase function and may explain
the declining rate at the highest concentration point.
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Figure 14: Unstimulated ATPase to characterize the specific activity of both enzymes.
Enzymatic assay without Poly-U RNA was initiated with 1 mM ATP. A Biomol Green reagent was
used to terminate the assay after 900 seconds. Each point is a well on a 96 well plate. Raw
absorbance was converted to a rate, nM/sec, using a known phosphate standard. Rates were
then plotted and fit with a linear regression to yield a slope kslow. Notice the Cysteine 292
containing mutant has about a 15 times faster ATP hydrolysis rate.
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Figure 15: Unstimulated ATPase assay to estimate affinity for ATP. Enzymatic assay without
Poly-U RNA was initiated with 1 mM Mg*ATP. A Biomol Green reagent was used to terminate
the assay after 900 seconds. Results were plotted and fit with Michaelis Menten to estimate
affinity for Mg*ATP. Notice the Cysteine 292 containing mutants all have higher rates of ATP
hydrolysis than wildtype, as well as higher Km for Mg*ATP.
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